Company news
Chongqing Genrix Biopharmaceutical Co., Ltd. Class A (SSE:688443) news
Chongqing Genrix Biopharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Feb 14, 2025: Announcement on the Voluntary Disclosure Regarding…
Press releases — page 2
Announcement on the Voluntary Disclosure Regarding the Initiation of Phase III Clinical Trial for GR1802 Injection in the Indication of Chronic Spontaneous Urticaria
February 13, 2025
Voluntary Disclosure Announcement on the Approval of Marketing Application for New Indications of Xeligekimab
January 20, 2025
Annual Earnings Preannouncement for 2024
January 17, 2025
Announcement on Voluntary Disclosure on the Acceptance of New Drug Application for Silevimig Injection
January 14, 2025
Announcement on Completing General Election of Board of Directors and Board of Supervisors, and Appointing Senior Management Members, Head of Internal Audit Department and Securities Affairs Representative
December 24, 2024
Announcement on Term Change and Election of the Board of Directors and the Board of Supervisors
December 6, 2024